GSK raises margin outlook, plots $2.5 billion restructuring to fast-track new drugs
By Bhanvi Satija and Raechel Thankam Job LONDON, July 28 (Reuters) - GSK launched a £1.9 billion ($2.52 billion) cost-savings effort on Tuesday to help fund the British drugmaker's expanded late-stage study roster, as CEO Luke Miels works to deliver on his promise of faster drug development. 
